Talphera (TLPH) Announces Board Changes

Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced as part of its commitment to operating with best practices in corporate governance, its Board of Directors has decided to reduce the size of the Board from ten to seven directors. Three directors, Howard Rosen, Richard Afable and Pamela Palmer have voluntarily agreed to resign from the Board of Directors, effective immediately. Dr. Palmer will continue in her current role of Chief Medical Officer and member of the executive leadership team, with a focus on successfully completing the Niyad™ registrational study later this year.

Adrian Adams, Chairman of the Talphera Board, said, "Our decision to reduce the size of the Board reflects our commitment to operating consistent with best practices in corporate governance and to better align the Board's size and composition with Talphera's current strategy. We believe having a smaller Board will improve efficiency as we focus on obtaining FDA approval for Niyad and enhancing value for shareholders. Our continuing directors provide diverse and deep experience in the pharmaceutical industry, including corporate finance, corporate development and M&A expertise."

Mr. Adams added, "Howie and Rick have made significant and valuable contributions to the Company over the many years they have served on the Board. We have appreciated their expertise, vision and judgment during times of significant transition for the Company. On behalf of the Board and the entire Company, I want to thank them both for their commitment to Talphera over the years. I also want to thank Pam, Howie and Rick for their support and professionalism in effecting these Board changes to ensure Talphera is in the best possible position to deliver value to our shareholders."

You May Also Be Interested In

• Illinois to require Medicaid coverage for proteomic preterm birth tests
• Coherus and Zumutor to run Phase 1 trial combining ZM008 and Loqtorzi
• Enanta Pharma loses appeal in Pfizer Paxlovid patent case